ConductScience.org, home

Trial · NCT04425902

Results by group665

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for CaffeineTreatment A: Probe Substrates37970Geometric Coefficient of Variation 31.1Hour*nanograms per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for CaffeineTreatment C: Probe Substrates + GSK3640254 200 mg42230Geometric Coefficient of Variation 32.4Hour*nanograms per milliliter (h*ng/mL)
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for CaffeineTreatment A: Probe Substrates39720Geometric Coefficient of Variation 30.6h*ng/mL
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for CaffeineTreatment C: Probe Substrates + GSK3640254 200 mg44440Geometric Coefficient of Variation 30.6h*ng/mL
Maximum Observed Plasma Concentration (Cmax) for CaffeineTreatment A: Probe Substrates4340Geometric Coefficient of Variation 22.1Nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for CaffeineTreatment C: Probe Substrates + GSK3640254 200 mg4110Geometric Coefficient of Variation 25.9Nanograms per milliliter (ng/mL)
Time to Cmax (Tmax) for CaffeineTreatment A: Probe Substrates2.000Full Range 1.00 to 6.00Hours
Time to Cmax (Tmax) for CaffeineTreatment C: Probe Substrates + GSK3640254 200 mg3.000Full Range 0.50 to 6.00Hours
Apparent Terminal Phase Half-life (t1/2) for CaffeineTreatment A: Probe Substrates5.380Geometric Coefficient of Variation 21.2Hours
Apparent Terminal Phase Half-life (t1/2) for CaffeineTreatment C: Probe Substrates + GSK3640254 200 mg6.085Geometric Coefficient of Variation 17.4Hours
AUC(0-t) for MetoprololTreatment A: Probe Substrates655.0Geometric Coefficient of Variation 135.2h*ng/mL
AUC(0-t) for MetoprololTreatment C: Probe Substrates + GSK3640254 200 mg807.3Geometric Coefficient of Variation 136.4h*ng/mL
AUC(0-infinity) for MetoprololTreatment A: Probe Substrates659.1Geometric Coefficient of Variation 134.4h*ng/mL
AUC(0-infinity) for MetoprololTreatment C: Probe Substrates + GSK3640254 200 mg813.1Geometric Coefficient of Variation 135.3h*ng/mL
Cmax for MetoprololTreatment A: Probe Substrates127.4Geometric Coefficient of Variation 90.0ng/mL
Cmax for MetoprololTreatment C: Probe Substrates + GSK3640254 200 mg141.1Geometric Coefficient of Variation 94.4ng/mL
Tmax for MetoprololTreatment A: Probe Substrates2.000Full Range 1.00 to 6.00Hours
Tmax for MetoprololTreatment C: Probe Substrates + GSK3640254 200 mg3.000Full Range 1.00 to 4.00Hours
t1/2 for MetoprololTreatment A: Probe Substrates4.872Geometric Coefficient of Variation 65.6Hours
t1/2 for MetoprololTreatment C: Probe Substrates + GSK3640254 200 mg5.342Geometric Coefficient of Variation 59.6Hours

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04425902/results